Taxane

Phase 3

ASTRAZENECA PLC (AZNCF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

DSKYFPhase 3$28.8B

✓Positive

Taxane Phase 3 Est. Readout

Taxane• Breast Cancer; HER2-positive; Metastatic1,157

Nov 2026~Confirmed

CT.gov

Competitive Landscape

0 competitors in Breast Cancer; HER2-positive; Metastatic

View Full Landscape

Drug Information

Target Indication

Breast Cancer; HER2-positive; Metastatic

Clinical Trial

NCT04784715

Last updated: 3/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

Quetiapine SRPhase 3

Anxiety Disorders

MEDI3250Phase 3

Healthy Japanese Children Age 2 Years Through 6 Years

ParoxetinePhase 3

Generalized Anxiety Disorder

AZD2265Phase 3

Metastatic Castration-resistant Prostate Cancer

CapivasertibPhase 3

Triple Negative Breast Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts